Medicaid can cover Ozempic for type 2 diabetes. Your pharmacy program, exact injection or tablet product, and approval rules decide whether it pays for your prescription. Ozempic is not FDA-approved for weight management, so weight-loss-only coverage should not be assumed. Find your state's published rule below, then use the five questions to check your prescription.
The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.
Here's the catch most people never hear: "covered" can involve different checks depending on where you live. In some programs the pharmacy checks existing records. In others, your doctor has to file paperwork. A non-preferred product may need evidence that a preferred one did not work or cannot be used. Your state is in the tables below.
No website, including this one, can promise your claim will be paid. The state sources and five questions below show you what to check next.
RX Index Decision Verdict: If you have type 2 diabetes, check your Medicaid pharmacy benefit before paying cash for Ozempic — start there.
- Best for: Medicaid members with type 2 diabetes, including anyone just told "needs prior authorization."
- Not ideal for: assuming diabetes rules cover weight loss, prediabetes, or polycystic ovary syndrome (PCOS) alone — and people with Medicare and full Medicaid, whose prescription benefit generally comes through Medicare.
- The factor that matters most: whether the exact product and documented use meet your pharmacy program's rules.
Does Medicaid cover Ozempic in your situation?
Medicaid checks why Ozempic was prescribed, the exact product, and the program's approval rules. Type 2 diabetes is an FDA-approved use. Weight loss alone is not, and federal law lets states exclude medicines when used for weight loss. Federal Medicaid drug rules allow prior authorization and other coverage limits.
Find your row:
| Your situation | Will Medicaid pay for Ozempic? | Your next step |
|---|---|---|
| You have type 2 diabetes | Can be covered when the exact product and program rules are met | Find your state in the table below |
| Type 2 diabetes plus qualifying heart or kidney disease | The injection has specific risk-reduction uses; the tablet's heart-risk indication differs | Have your clinician document the relevant condition and check the product's rule |
| Weight loss only, no diabetes | Usually no | Read the weight-loss section |
| Prediabetes, PCOS, or insulin resistance only | These do not establish coverage under a type 2 diabetes rule | Ask your doctor which treatment and covered-use rule fit your actual diagnosis |
| The pharmacy rejected it | Depends on the reason | Use the denial decoder |
| You have Medicare and full Medicaid | Prescription coverage generally comes through Medicare | Read the Medicare section |
| Under 21 | Ozempic's label is for adults | Ask about Medicaid's under-21 benefit (EPSDT) |
| You don't know which plan handles your prescriptions | Unknown until you check | Call the pharmacy number on your Medicaid card |
Think of Ozempic and Wegovy as the same key cut for two different doors. Both are semaglutide, made by Novo Nordisk. Ozempic's label opens the diabetes door. Wegovy's label opens the weight-management door. Medicaid looks at which door you're trying.
The right next step isn't the same for everyone. It depends on your state, your plan's drug list, why you're being treated, pill or shot, and your budget. The RX Index's Find My GLP-1 Path tool is free, takes about 2 minutes, and needs no signup. Answer a few quick questions about your goals, budget, insurance, and situation. Pick Medicaid when it asks how you'll pay, and it shows state and plan coverage guidance for your situation. Your Medicaid plan still makes the final call on coverage and cost.
Ozempic Medicaid coverage by state (2026)
All 50 states and the District of Columbia have a Medicaid prescription-drug benefit. That does not guarantee a particular Ozempic claim. The rows below show the product status and approval rules we could establish from official documents; unresolved findings stay marked as unknown.
Three checks you may encounter: A program can combine these, and the pen and pill can follow different rules.
- "Diagnosis on file" checks. The pharmacy's system checks existing records or a diagnosis code. A claim may still face other limits. Examples: California, Idaho, Massachusetts, New York.
- "Paperwork" checks. Your doctor sends a prior authorization — an approval request. It may need proof of diabetes, an A1C (a blood test that reflects roughly 3 months of blood sugar), or treatment history. Examples: Florida, Indiana, South Carolina, Tennessee.
- "Try something else first" checks. A non-preferred product may need a preferred-drug trial or a documented medical exception. Examples: Maine, Oklahoma, Arizona — and Kentucky for the pill.
Two words you'll see in the table. Preferred means the program favors that product in its drug group; it can still need approval. Non-preferred means another product is favored and extra requirements may apply. It does not automatically mean "not covered."
We checked the documents supporting the findings below on October 22, 2026. Each row keeps the source's own date. A row may establish preferred status without settling every approval requirement. Some sources say "injection" without naming the device; that does not establish coverage for every injection product, including single-dose prefilled syringes. "Fee-for-service" (FFS) means the state pays claims directly. "Atherosclerotic cardiovascular disease" means heart or artery disease caused by plaque buildup.
Find your state
Choose a state to see its published finding or lookup route. Both full tables remain below.
| State | Ozempic pen / injection entry | Ozempic pill | What the published rule says | Source (document date) |
|---|---|---|---|---|
| Alaska | Clinical criteria published; preferred status not confirmed | Expressly included in the same clinical criteria | The criteria include a qualifying diagnosis-code pathway and clinical review. Clinical review requires type 2 diabetes and one of these: A1C above 7% within 60 days, qualifying artery disease, or qualifying chronic kidney disease. It also lists a diabetes care plan and at least 3 months of metformin or a documented contraindication. Weight-control use is excluded. Ask which approval pathway applies to your claim | Alaska semaglutide criteria, p. 2 (updated 9/18/2026) |
| Arizona (AHCCCS) | Not on the preferred list reviewed | Not separately confirmed | The October preferred GLP-1 list names Byetta, liraglutide, Mounjaro, Trulicity and Victoza. A non-preferred request needs prior authorization based on step therapy or documented medical necessity. AHCCCS contractors must follow the state's preferred selections; ask your plan for the exact Ozempic prior authorization rule | AHCCCS contractor memo, pp. 1, 7 (6/8/2026; changes effective 10/1/2026) |
| Arkansas | Non-preferred; prior authorization required | Not separately confirmed | The general GLP-1 section lists Ozempic as non-preferred. A separate section has criteria for Ozempic injection for type 2 diabetes with chronic kidney disease. Ask which prior authorization pathway applies; the chronic kidney disease-specific heading is not proof that all Ozempic requests require chronic kidney disease | Arkansas Medicaid clinical criteria, printed pp. 52–53, 540 (book revised 10/1/2026; chronic kidney disease section updated 7/16/2025) |
| California (Medi-Cal Rx) | Type 2 diabetes coverage described in the FAQ | Not separately confirmed | For the type 2 diabetes claim pathway, the correct diagnosis code is required; a missing or incorrect code causes Reject Code 80. Prior authorization requests for other non-weight-loss uses may be reviewed for medical necessity. Weight-loss use is excluded for ages 21+ from 1/1/2026; requests for members under 21 receive EPSDT review | Medi-Cal Rx FAQ v3.0, pp. 4–5 (4/6/2026) |
| Connecticut (HUSKY Medicaid) | Preferred; diagnosis code required | Non-preferred; clinical prior authorization | Preferred injection claims require the appropriate diagnosis code. Tablet requests need documented type 2 diabetes and the non-preferred clinical review, generally including a preferred-agent trial or a documented exception. The criteria describe a separate medical-necessity route for documented needle phobia | Connecticut PDL, p. 5 (updated 10/21/2026); GLP-1 criteria, pp. 1, 3–5 (revised 7/1/2026) |
| Delaware (FFS criteria) | Preferred; clinical prior authorization | Non-preferred; clinical prior authorization | All GLP-1 agents require prior authorization. For non-preferred products, the PDL requires two preferred products first; tablets also require a medical reason the injection cannot be used. These published prior authorization criteria are for FFS members; managed-care members use their health plan's criteria | Delaware Medicaid PDL, cover and printed p. 27 (effective 10/5/2026) |
| District of Columbia (fee-for-service) | Preferred injection entry | Non-preferred; prior authorization | This is the fee-for-service list. The tablet requires prior authorization; members in managed care should check their plan's pharmacy rules | DC preferred drug list (9/18/2026) · DHCF program scope |
| Florida | Preferred; clinical prior authorization | Preferred; clinical prior authorization | Age 18+, type 2 diabetes, documented A1C of at least 6.5% measured within 6 months, and a metformin trial and failure within 2 years unless contraindicated or not tolerated. Approval also depends on the remaining clinical criteria | Florida GLP-1 criteria_Receptor_Agonist_10.01.2026.pdf) (October 2026 posted file; last printed revision 7/2/2026) |
| Georgia (Medicaid FFS) | Preferred; prior authorization and quantity limits | Not separately confirmed | Current Ozempic injection criteria specify age 18+, type 2 diabetes and A1C of at least 6.5%, for blood sugar control or the specified heart/kidney-risk uses. The current Ozempic section does not list a metformin-first requirement. Managed-care members should check their plan's criteria | Georgia antidiabetic criteria, pp. 1, 4 (revised 7/1/2026; posted 8/19/2026); Georgia PDL (effective 10/1/2026) |
| Idaho | Preferred; type 2 diabetes diagnosis-code rule | Non-preferred; prior authorization | For the preferred pen, a type 2 diabetes code must be in the member's record or submitted with the pharmacy claim. Non-preferred requests generally need adequate trials of two preferred agents or a contraindication, plus documented medical necessity | Idaho PDL and prior authorization criteria, pp. 1, 25 (effective 7/1/2026; revised 9/1/2026) |
| Illinois (state PDL) | Non-preferred | Preferred with prior authorization | The October list explicitly treats the pen and tablets differently. Ask your pharmacy benefit administrator for the clinical requirements for your exact formulation; the PDL listing alone does not establish approval | Illinois Medicaid PDL, p. 24 (effective 10/1/2026) |
| Indiana | Preferred; prior authorization | Not separately confirmed | For type 2 diabetes requests: age 18+, documented type 2 diabetes, a metformin trial of at least 90 days within the past 120 days unless not tolerated or contraindicated, and baseline A1C from the past 90 days. The policy also contains a separate pathway for certain fatty liver diseases (MASH/MASLD) | Indiana GLP-1 criteria, p. 2 (7/1/2026) |
| Iowa (state PDL) | Ozempic listed as preferred with prior authorization; formulation not specified in this list | Not separately confirmed | The current list marks Ozempic “P” with Comment 11, meaning prior authorization required. Confirm the exact product and clinical requirements with your current pharmacy benefit administrator. The move to one statewide pharmacy benefit starts 12/1/2026 | Iowa PDL, pp. 1, 45 (effective 10/1/2026); Iowa pharmacy program |
| Kansas | Preferred; clinical prior authorization | Not separately confirmed | For blood-sugar-control requests, the criteria require a recent A1C above the prescriber's stated goal and a metformin pathway: a qualifying prior trial, concurrent metformin in specified circumstances, or a contraindication. Separate criteria apply to approved heart/kidney-risk uses. Ask which pathway fits the prescribed indication | Kansas PDL, p. 20 (updated 8/1/2026); type 2 diabetes clinical criteria, pp. 1–3 (revised 4/16/2025; currently linked by KDHE) |
| Kentucky | Preferred with prior authorization | Non-preferred; prior authorization | The current PDL distinguishes the forms. Clinical criteria require documented type 2 diabetes; tablet requests also face the non-preferred requirements, including preferred-agent trials or a documented exception. Ask for the criteria for the exact form on the prescription | Kentucky PDL, p. 22; prior authorization criteria, pp. 156–159 (October 2026) |
| Maine (MaineCare) | Non-preferred; prior authorization | Not separately confirmed | The PDL lists Rybelsus, Trulicity and Victoza as preferred. Preferred-drug trials are required in the stated step order unless an acceptable clinical exception is documented, such as a contraindication or significant interaction | MaineCare PDL, p. 11 (posted file 10/9/2026) |
| Maryland (Medicaid FFS) | Ozempic listed as preferred; formulation not specified | Not separately confirmed | The FFS PDL lists Ozempic as preferred. This row confirms list placement only; it does not establish all diagnosis, prior authorization or quantity rules. HealthChoice members should check their own health plan's drug list | Maryland PDL, p. 19 (effective 7/1/2026; updated 8/6/2026); program drug-list page |
| Massachusetts (MassHealth) | Preferred in the cited state drug-list update | Not separately confirmed | The published point-of-sale rule generally allows an injection claim to pay when a diabetes diagnosis is present and the claim is within quantity limits. Ask whether the claim meets those edits or requires prior authorization | MassHealth Prescriber e-Letter, p. 2, Table 2 (March 2026 corrected issue) |
| Michigan | Preferred; prior authorization and quantity limits | Non-preferred; prior authorization and quantity limits | The common formulary explicitly lists both forms with prior authorization and quantity limits. Medicaid health plans follow the state's Single PDL for these categories. Ask for the current clinical criteria and product-specific quantity limit | Michigan Common Formulary, pp. 2, 68 (effective 10/1/2026; revised 9/28/2026); clinical criteria, p. 147 (10/1/2026) |
| Minnesota (FFS and managed care) | Injection listed as preferred | Not separately confirmed | The Uniform PDL lists Ozempic injection as preferred for both FFS and managed care. This verifies list placement, not every clinical edit. Ask your benefit administrator whether the prescription requires diagnosis documentation, prior authorization or a quantity override | Minnesota Uniform PDL, pp. 1, 22 (effective 8/4/2026) |
| Missouri (MO HealthNet) | Ozempic listed as preferred on the prior authorization form | Not separately confirmed | The preferred-agent section of the prior authorization form requires a documented diabetes diagnosis and diagnosis code. The form does not establish that a diagnosis alone guarantees approval or separately confirm Ozempic tablets | Missouri GLP-1 prior authorization form, p. 1 (form dated April 2026; July upload) |
| Montana | Preferred injection entry; electronic edits apply | Non-preferred | Electronic checks apply to this class. Non-preferred requests generally require two preferred-drug trials of six months each; ask about an exception if a trial is medically inappropriate | Montana PDL (9/10/2026) |
| Nebraska | Preferred non-tablet entry; clinical criteria apply | Non-preferred; new-drug criteria apply | Preferred GLP-1s require type 2 diabetes and a failed or intolerable metformin trial; the metformin trial is not required for type 2 diabetes with established atherosclerotic cardiovascular disease. Tablets have additional non-preferred/new-drug requirements | Nebraska PDL (10/1/2026) |
| Nevada | Preferred; prior authorization | Preferred; prior authorization, effective 8/1/2026 | Type 2 diabetes, A1C results from the past 180 days, and other clinical checks. Not for weight loss without a type 2 diabetes indication. Nevada uses one list for all Medicaid plans | PDL (1/5/2026) · tablet update (7/31/2026; effective 8/1) · clinical manual, Appendix A, KK (8/3/2026 compilation) · statewide-list notice (5/12/2026) |
| New York (NYRx) | Preferred | Non-preferred | A preferred drug can pay without prior authorization when the required facts are already in Medicaid claims history. Non-preferred drugs need prior authorization. GLP-1 drugs are excluded when used for weight loss | NYRx PDL (rev. 10/22/2026) · NYRx coverage rules (rev. 7/16/2026) |
| North Carolina | Preferred | Non-preferred | Clinical criteria apply to the diabetes class | NC Medicaid PDL (10/1/2026) |
| North Dakota | Preferred injection entry; no prior authorization listed | Preferred; no prior authorization listed | Both formulations are explicitly preferred without prior authorization in the list for fee-for-service and expansion members. The state's general coverage and diagnosis rules still apply | North Dakota PDL, version 2026.7 (10/1/2026; dosage-form list p. 293) |
| Oklahoma (SoonerCare) | Tier 3; prior authorization | Not separately identified; confirm the exact product | Type 2 diabetes. Generally requires a three-month trial of a Tier 2 GLP-1, such as Trulicity or Victoza. Tier 2 metformin rules and documented clinical exceptions apply | SoonerCare diabetes criteria (2026 page; checked 10/22/2026) |
| Oregon (fee-for-service/open-card) | Non-preferred; prior authorization | Non-preferred; prior authorization | Type 2 diabetes, plus either failure to meet A1C goals with metformin or a documented contraindication to metformin. Managed-care members should check their coordinated care organization's rules | Oregon detailed PDL lookup (checked 10/22/2026) · GLP-1 criteria (P&T review 8/2026) · program scope |
| Pennsylvania | Preferred; prior authorization | Preferred; prior authorization | Statewide-PDL clinical approval guidelines apply to both fee-for-service and Medicaid managed care. Check the plan for its forms, submission procedure and quantity limits | Pennsylvania statewide PDL (January 2026 v16; listed as current on 10/22/2026) |
| South Carolina | Preferred; prior authorization | Not addressed in the checked injectable criteria | For adults: type 2 diabetes, metformin trial and failure or a documented intolerance/contraindication, and baseline A1C from the past three months. Confirm tablets separately | South Carolina injectable GLP-1 criteria (rev. 10/1/2026) |
| Tennessee (TennCare) | Preferred; prior authorization | Non-preferred; prior authorization | Provide lab evidence of type 2 diabetes, such as a qualifying historical A1C. Non-preferred requests generally need trials of two preferred drugs or documented reasons they cannot be used | TennCare GLP-1 prior authorization form (October 2026) |
| Texas | Clinical criteria posted; preferred status not confirmed | Ozempic tablets not separately named in the checked criteria | The posted criteria for the listed Ozempic pens require age 18+, type 2 diabetes documented in the past year, an A1C test in the past 180 days, and medication-history or qualifying heart/kidney history, plus safety checks. Confirm formulary status and the exact product with the plan | Current GLP-1 criteria (4/3/2026) · criteria index (September revision still marked pending on 10/22/2026) |
| West Virginia | Preferred injection entry; clinical criteria apply | Non-preferred; prior authorization | Preferred agents can be authorized for type 2 diabetes. The non-preferred pathway adds A1C and treatment-history requirements, including trials of the preferred agents; exceptions may apply | West Virginia PDL (Q4 v7; effective 10/1/2026) |
| Wisconsin (ForwardHealth) | Preferred; diagnosis restriction | Non-preferred; prior authorization and diagnosis restriction | The list identifies a diagnosis restriction for both formulations. Confirm the diagnosis and other claim requirements with the pharmacy | ForwardHealth quick reference (effective 9/1/2026) |
States we haven't confirmed yet. For these, we couldn't confirm a current Ozempic rule from a readable source. That's not a "no." Use the official lookup route below, search the current list for "Ozempic," or call the pharmacy number on your card.
| State | Where to check |
|---|---|
| Alabama | Alabama Medicaid PDL page or official NDC lookup. Current Ozempic placement and criteria were not confirmed |
| Colorado | Health First Colorado pharmacy resources. Ask the pharmacy benefit administrator for the current Ozempic rule |
| Hawaii | Med-QUEST pharmacy drug-coverage information, or call your health plan's pharmacy number. Exact current Ozempic criteria were not confirmed |
| Louisiana | Louisiana Medicaid Single PDL, also linked by Louisiana Healthcare Connections. Ask which Ozempic rule applies to the exact product on your prescription |
| Mississippi | Mississippi Medicaid or the pharmacy number on your Medicaid card. Ask for the current Ozempic list entry and approval rule |
| New Hampshire | New Hampshire Medicaid pharmacy and current/archived lists — confirm the effective date and exact Ozempic formulation |
| New Jersey | New Jersey Medicaid — ask the pharmacy contact for your health plan |
| New Mexico | New Mexico Health Care Authority — ask your Medicaid health plan to confirm the exact Ozempic product |
| Ohio | Ohio Medicaid pharmacy benefit manager — check the current unified preferred drug list |
| Rhode Island | Rhode Island October 2026 PDL |
| South Dakota | South Dakota GLP-1 prior authorization form |
| Utah | Utah Medicaid pharmacy — check the fee-for-service list or your managed-care plan, as applicable |
| Vermont | Vermont PDL |
| Virginia | Virginia Medicaid pharmacy and formularies |
| Washington | Apple Health preferred drug list |
| Wyoming | Wyoming current PDL page — current list effective June 8, 2026; confirm the exact formulation |
If your Medicaid medical benefits come through a company like Molina, Aetna Better Health, or UnitedHealthcare Community Plan, that's managed care. The pharmacy benefit can still follow a state or common drug list. If you're not sure who handles it, call the pharmacy number on your card and ask. Our plan-by-plan Medicaid GLP-1 research explains how those state and plan roles fit together.
Say you're 52, you have type 2 diabetes, and you're on Medicaid in Michigan. The pharmacy says your Ozempic pen "needs approval." You look it up, see "preferred," and wonder why. In Michigan, the preferred pen still needs clinical prior authorization. Ask your doctor's office whether it sent the request and required records. That identifies the next step; approval remains unknown until the program reviews the request.
Does Medicaid cover Ozempic for weight loss?
Do not assume so. Ozempic is FDA-approved for adults with type 2 diabetes, not for weight management, and federal law lets states exclude medicines when used for weight loss. A state's coverage of Wegovy or Zepbound does not establish weight-loss coverage for Ozempic.
We know that's not what a lot of people hoped to read. Here's what's still true and useful.
There is a weight-management version of the same medicine. Wegovy is semaglutide with a weight-management label. Whether your state's Medicaid covers it is a separate question. Our state-by-state weight-loss tracker tracks those policies with dates and sources. Several programs cut weight-loss coverage: South Carolina at the end of 2025; California, New Hampshire, and Pennsylvania on January 1, 2026; Utah's fee-for-service program on June 30; and Rhode Island on October 1. In Massachusetts, UnitedHealthcare Community Plan's notice confirms a July 3 change to comply with MassHealth. Age, use, and plan exceptions need their own check.
A weight-loss exclusion does not tell you the diabetes rule. If you have type 2 diabetes and got a letter about weight-loss drugs, check the separate diabetes criteria. California's Medi-Cal, for example, ended weight-loss-only coverage for members age 21 and older but kept Ozempic for type 2 diabetes with the required diagnosis coding.
"Off-label" isn't automatically "never." Medicaid's legal definition of a covered use includes FDA-approved uses and uses backed by certain official drug reference books, called compendia (Social Security Act §1927). But states can still exclude weight-loss uses — and New York's rules, for example, name Ozempic as excluded for weight loss.
Indiana's Ozempic policy, for example, has a separate approval pathway for certain fatty liver diseases. That is a state coverage rule, not an FDA approval for Ozempic to treat those diseases. Your prescriber must check the full criteria.
Prediabetes and PCOS are real — but they're not type 2 diabetes. These diagnoses alone do not meet a type 2 diabetes coverage rule. If your numbers are creeping up, ask your doctor when to re-test. Never ask a doctor to code a diagnosis you don't have. Ask which treatment and covered-use rule fit your actual diagnosis. More: Ozempic coverage for prediabetes.
What does your doctor need to send for Ozempic prior authorization?
Prior authorization is your prescriber's request for the Medicaid program to approve payment under its rules. For Ozempic, the reviewed policies ask for diagnosis records and, in some programs, recent blood sugar results or previous diabetes treatments. The exact list depends on the program and product.
Here's what the state rules we read most often ask for. Use it as a prep list, not a national rulebook:
| What's often required | Where we saw it |
|---|---|
| A diagnosis code or diagnosis record | California, Idaho, Missouri, Wisconsin, Massachusetts |
| A recent A1C, using the policy's time window | Florida: 6 months; Indiana's initial diabetes request and South Carolina: 3 months; Nevada: 180 days |
| A metformin trial, or a documented medical exception | Florida, Indiana, South Carolina, Alaska's clinical-review pathway, Oregon's FFS pathway |
| A preferred GLP-1 trial, or a documented exception | Maine, Oklahoma, Idaho's non-preferred pathway, Kentucky's tablet pathway |
| Your full medication list, including any other GLP-1 | Indiana's criteria check for overlapping treatment |
| Relevant heart or kidney disease records | Alaska has a separate qualifying heart/kidney alternative to its A1C threshold; type 2 diabetes and other criteria still apply |
If you have type 2 diabetes plus established cardiovascular disease or chronic kidney disease, tell your doctor to include it. Ozempic injection has additional FDA-approved risk-reduction uses for these groups on the injection label. Your Medicaid program's coverage criteria still apply.
A short text you can send your doctor's office:
"Hi — my Medicaid pharmacy says my Ozempic needs prior authorization. My pharmacy benefit is [name], and my prescription is for [exact product]. Can you check the current rule and send the diagnosis records, dated labs, and treatment history it requires? If a preferred-drug trial applies, can you tell me what that means for me?"
More help: the documents a GLP-1 prior authorization needs and what to do when your plan wants a different drug first.
How to check your own Ozempic coverage: 5 questions
Start with these five questions when you call. They help identify the right policy and any missing records; a final approval may still need your prescriber's request. Write the answers down as you go.
| Ask this | Why it matters |
|---|---|
| 1. "Who handles my prescription claims?" | Your health plan and your pharmacy plan can be different. The pharmacy number on your card reaches the right one |
| 2. "Which Ozempic injection or tablet product is on my prescription?" | Programs can list products differently. Don't assume one covers another |
| 3. "Is it covered for my diagnosis?" | Coverage follows the reason it was prescribed |
| 4. "Is it preferred? Does it need prior authorization or another drug first?" | "Preferred" can still need approval. "Non-preferred" can still be covered |
| 5. "What will I pay for this exact fill — and if it's rejected, why?" | The exact reason tells you who fixes it |
What to say when you call the pharmacy number on your Medicaid card:
"I have [plan name] Medicaid and a prescription for Ozempic [exact injection or tablet product]. Is this product covered for my diagnosis? Does it need prior authorization, or do I have to try another drug first? Can you send me the current rule? If it was rejected, what's the exact reason and who needs to fix it? If it's approved, what will I pay?"
Your checklist (print it or copy it — nothing here is saved):
- My state and plan: ______
- Who handles my prescriptions (and their phone number): ______
- Exact injection or tablet product, strength, and days' supply (copy from the prescription): ______
- My diagnosis, as my doctor wrote it: ______
- Preferred / non-preferred / not sure: ______
- Prior authorization needed? Another drug first? ______
- Records my doctor must send: ______
- My copay for this fill (write "not confirmed" until someone tells you): ______
- Rejection message or denial letter, if any: ______
- Who acts next, and any deadline on the notice: ______
- Date I called, person I spoke with, reference number: ______
Why did Medicaid deny my Ozempic?
An Ozempic rejection can involve missing paperwork, a billing mismatch, or a coverage rule the request does not meet. The pharmacy message or denial letter tells you which problem to address and who needs to act next.
| What the pharmacy or letter says | What it may mean | Who acts next |
|---|---|---|
| "Prior authorization required" | Approval is needed, pending, expired, or not matched to this claim | Doctor and pharmacy check the request's status and exact product |
| "Diagnosis does not meet criteria" (in California, Reject Code 80) | The claim is missing the type 2 diabetes code, or it went in as weight loss | Pharmacy and doctor check the code — it must match your real diagnosis |
| "Non-preferred" or "step therapy" | A preferred-drug trial or another non-preferred approval requirement may apply | Doctor checks the exact rule, your history, and any exception |
| "Criteria not met" | Required evidence is missing, or the documented case does not meet the rule | Doctor checks the reason, corrects missing records, or considers an exception/appeal |
| "Quantity limit" or "refill too soon" | Billing, dose, or timing issue | Pharmacist compares the claim to the prescription |
| "Not covered for weight loss" | The use is excluded | Ask for the written rule; talk with your doctor about what's covered for you |
| "Other coverage" or "wrong payer" | Another insurer or pharmacy benefit may be responsible | Pharmacy confirms the correct payer and billing order |
| Renewal denied | A past approval doesn't cover the next fill | Doctor checks the renewal rule and needed records; check the notice deadline |
A missing diagnosis code is one fixable problem. If you have documented type 2 diabetes, ask your doctor's office, "Was this sent with my diabetes diagnosis?" The code must match your actual record; correcting it does not settle any other approval requirements.
How to appeal
Start with the deadline printed on your notice. If you're in a Medicaid health plan, you generally appeal to the plan first and have 60 calendar days from the date on the denial notice to file. If waiting could seriously harm your health, ask for a fast (expedited) decision and have your doctor explain why. If the plan says no again, you can ask for a state fair hearing. If you're in your state's own fee-for-service program, ask the state how to request a hearing.
If an existing approval is being cut short, ask immediately whether your benefits can continue during the appeal. That request can have a much shorter deadline, and you may owe the cost if the final decision goes against you.
If you're about to run out of Ozempic, call your doctor and pharmacist now and ask how to avoid a gap in treatment. Full guides: how to appeal a GLP-1 denial, our appeal letter template, and what pharmacy rejection codes mean.
How much does Ozempic cost with Medicaid?
If Medicaid covers your Ozempic, your program may charge a copay, and some members pay nothing. Federal rules limit drug cost sharing. Your pharmacy can tell you the exact amount for your fill.
Under 42 CFR 447.53, the limit depends on income, exemptions, and whether the drug is preferred. The dollar limits are adjusted each year, so the rule's $4 and $8 base figures are not a current price quote. Some members above 150% of the federal poverty level can face a non-preferred-drug copay of up to 20% of the state's cost. If your prescriber finds that a preferred drug would work less well or cause adverse effects, the program must have a timely process to apply preferred-drug cost sharing to the medically necessary non-preferred drug.
What about everything else people try?
| Option | Can a Medicaid member use it? | What it costs (checked Oct 22, 2026) |
|---|---|---|
| Medicaid pays | Yes, when your program's rules are met | Ask the pharmacy for your actual copay; some members pay $0 |
| Ozempic $25 commercial-insurance savings card | No. Novo's copay-offer terms exclude Medicaid members | — |
| Novo's free-drug Patient Assistance Program | No while you're on Medicaid. Its rules exclude anyone enrolled in or eligible for Medicaid | — |
| NovoCare Pharmacy self-pay — pen | Yes, if Ozempic is prescribed for an FDA-approved use | Eligible new patients: $199 a fill for the first two 28-day fills (0.25 or 0.5 mg; deadlines below). Standard price: $349 (0.25–1 mg) or $499 (2 mg) per box |
| NovoCare Pharmacy self-pay — pill | Same FDA-approved-use rule | $149 (1.5 mg), $199 (4 mg), $299 (9 mg) per 30 tablets. The 1.5 mg strength is the starting tablet and is not effective for blood sugar control |
| Manufacturer list price — Ozempic injection | This is a benchmark, not a pharmacy cash quote or your Medicaid bill | Around $1,000 before discounts. Novo announced a $675 monthly list price effective January 1, 2027; that change does not change its direct self-pay prices |
Sources: NovoCare Pharmacy terms and prices, Ozempic savings offer, Novo PAP rules, Novo list-price announcement.
Check the introductory offer's deadlines. The $199 pen offer is for eligible patients who have never filled Ozempic injection through NovoCare Pharmacy or NovoCare Legacy Pharmacy. The prescription must be written and received by the pharmacy by December 31, 2026, and shipped by January 31, 2027.
Read the receipt carefully. A pen "month" at NovoCare is one box, defined as 28 days. If you buy three boxes at once, the $349 price is $1,047 due that day for 84 days. At $499, three boxes cost $1,497. Tablet prices cover 30 tablets. These are medicine prices; a separate clinician or telehealth service can add its own charges. NovoCare's self-pay terms say you cannot submit the purchase to Medicaid or another insurer for reimbursement.
One catch for weight-loss buyers: NovoCare's self-pay offer requires that Ozempic be prescribed for an FDA-approved use. Weight loss isn't one. Wegovy is the semaglutide brand with a weight-management label — see our guide to the cheapest way to get Wegovy without insurance.
Compare your confirmed Medicaid copay with the full self-pay cost before choosing. If you have type 2 diabetes, check the coverage and prior-authorization path first.
Does Medicaid cover the Ozempic pill?
Medicaid can cover the Ozempic pill for type 2 diabetes, but its preferred status and approval rules can differ from the pen. The Ozempic pill is semaglutide in tablet form (1.5, 4, and 9 mg) for adults with type 2 diabetes. In the U.S., it's replacing Rybelsus, the older semaglutide tablet. Novo Nordisk announced U.S. availability starting May 4, 2026.
From our state table:
- Pill preferred: Florida, Illinois (preferred over the pen), Nevada, North Dakota, Pennsylvania.
- Pill non-preferred: Connecticut, Delaware's FFS list, DC's FFS list, Idaho, Kentucky, Michigan, Montana, Nebraska, New York, North Carolina, Oregon's FFS list, Tennessee, West Virginia, Wisconsin.
If your program prefers the pen, ask whether the tablet has extra approval requirements. The two forms aren't swapped milligram for milligram — the tablet label has its own doses, and your doctor chooses. The pill's label covers blood sugar control and lowering the risk of major heart events in adults with type 2 diabetes at high risk. The kidney-disease use is on the injection label only.
More: Ozempic pill reviews and how to get the Ozempic pill online.
What if you have Medicare too, or you're under 21?
If you have Medicare and full Medicaid, check your Medicare drug plan's Ozempic rules. Medicare generally handles your prescription benefit; that does not guarantee a particular prescription is covered. People under 21 on Medicaid have a separate benefit, called EPSDT, that looks at medical need case by case.
Medicare and Medicaid together. Medicare.gov says that if you have Medicare and full Medicaid, Medicare covers your prescription drugs. You're placed in a Medicare drug plan automatically and get Extra Help with costs without a separate application. So check your Medicare drug plan's rules for Ozempic, not your state's Medicaid list. One thing that trips people up: the separate Medicare GLP-1 Bridge offers eligible Medicare members Wegovy, Zepbound KwikPen, or Foundayo for $50 per monthly supply. It does not include Ozempic. More: does Medicare cover Ozempic and the GLP-1 Bridge for people with both programs.
Under 21. EPSDT (Early and Periodic Screening, Diagnostic, and Treatment) is Medicaid's benefit for members under 21, including ages 18 to 20. It provides added protections for medically necessary care, so an adult exclusion may not settle an individual request. California's Medi-Cal, for example, reviews under-21 GLP-1 requests case by case. Ozempic's label is for adults; safety and effectiveness in children haven't been established. A teen's doctor is the right person to decide which medicine fits. See GLP-1 coverage for teens.
What if you're losing Medicaid?
If you receive an end-of-coverage notice, confirm the date, your appeal rights, and your next prescription benefit before your next fill. New federal work requirements are another reason some adults should plan now.
CMS's current rule generally requires states to start by January 1, 2027; states can start sooner. It applies to certain adults ages 19 to 64, including many who qualify through Medicaid expansion, who are not pregnant or enrolled in Medicare. It can be met through 80 hours a month of qualifying work, community service, or work programs; at least half-time education; or qualifying monthly earnings. School does not have an 80-hour rule. Exemptions include people who are medically frail, some caregivers, and other groups. Your state's Medicaid office can tell you what applies to you.
Three things to do now:
- Renew on time and answer every letter from your Medicaid office.
- Ask about exemptions and what records your state needs. A diabetes diagnosis alone does not establish that you qualify for an exemption.
- Line up your next coverage. If you're moving to a job-based plan, check whether it covers Ozempic for type 2 diabetes before your Medicaid ends. With eligible commercial coverage, Novo's copay offer advertises as little as $25, with a maximum benefit of $100 per one-month prescription. Your final cost depends on your covered prescription and copay.
If your Medicaid has ended and you now have commercial insurance, Ro's free checker can report your new plan's coverage for the Ozempic pen. Ro currently says people with Medicaid are not eligible for treatment. If you qualify for treatment and choose a paid Ro Body membership, its insurance concierge can help with prior authorization. The free report does not include that service, and medication costs are separate from membership.
Check your new coverage with Ro
More: how to get insurance to cover a GLP-1.
No covered path? Here's the honest picture
If your program excludes the requested use and no covered exception applies, more paperwork alone will not make Ozempic covered. You can still talk with your doctor about other covered treatments, or about paying yourself — but that's a budget decision you should make with clear eyes.
- Start with your doctor. Ask what is covered for you. There may be a covered option you haven't tried.
- Check Wegovy in your state. It's the semaglutide brand approved for weight management. Some states still cover it — see the state tracker.
- If you pay yourself, don't sign up for anything you can't keep paying for. If cost could interrupt treatment, ask your prescriber how to avoid a gap and how any restart would be managed.
- Compounded semaglutide is sold by some online programs for cash. Compounded drugs are not FDA-approved, and the FDA doesn't review them for safety, effectiveness, or quality before they reach patients. Semaglutide is no longer on FDA's shortage list. Legal compounding is limited to specific conditions; the end of the shortage does not make every compounded prescription illegal or every online offer lawful. FDA says these products should be used only when a patient's medical need cannot be met by an FDA-approved drug. Read where compounded GLP-1s stand now before considering one.
Need a clinician who takes your coverage? Ask the member-services number on your card for an in-network primary-care clinician or diabetes specialist. If you do not know which program to call, use the official Medicaid state contact directory.
Will the BALANCE program change Ozempic coverage?
Not automatically. BALANCE is a voluntary federal program that lets state Medicaid programs buy GLP-1s like Ozempic at lower prices. CMS says it won't guarantee coverage for any individual, and states choose whether to join (from May 2026 through January 1, 2027).
CMS includes both currently covered uses, such as type 2 diabetes, and weight management in the model. State participation, the covered use, and approval criteria still matter. Our BALANCE state tracker shows where each state stands.
How we checked
What we actually verified
- On October 22, 2026, we read: the Ozempic injection label (revised May 2026) and tablet label (revised January 2026); the federal Medicaid drug law and copay and appeal rules; the documents supporting the main table's findings; Medicare.gov's coverage pages; and CMS's BALANCE, EPSDT, and work-requirement guidance. We also checked FDA's current shortage and compounding guidance.
- Prices and programs, checked October 22, 2026: NovoCare Pharmacy's self-pay terms and prices, Novo's savings-offer terms, Novo's Patient Assistance Program rules, Novo's list-price announcement, and Ro's eligibility page. These are the companies' own statements.
- State table: 35 entries have at least one verified drug-specific finding; 16 states remain unresolved. The full list covers all 50 states plus DC. Some findings establish list placement only, and unconfirmed product details stay labeled. Each main-table row shows the source's own date.
- What we didn't do: check your personal benefits, call any plan, or predict an approval. Your plan's written rules and your pharmacy's answer are what count.
See how we research and verify.
Frequently asked questions
Does Medicaid cover Ozempic in every state?
All 50 states and DC have a Medicaid prescription-drug benefit, but that does not guarantee your Ozempic claim. The exact product, documented use, and program rules matter. Some programs check existing records, some require prior authorization, and some prefer another drug first. Find your state in our table.
Does Medicaid require prior authorization for Ozempic?
Often, but not always. A preferred drug can still need prior authorization. New York can process a preferred drug without manual approval when the required facts are already in claims history, and North Dakota lists both Ozempic forms as preferred without prior authorization. Your program's other claim rules still apply.
How much does Ozempic cost with Medicaid?
Your program may charge a copay, and some members pay nothing. Federal limits depend on income, exemptions, and preferred status. The rule's $4 and $8 base figures are indexed; they are not a verified 2026 quote. Ask the pharmacy for the cost of your exact fill.
Will Medicaid cover Ozempic for weight loss?
Usually no. Ozempic isn't FDA-approved for weight loss, and federal law lets states exclude weight-loss drugs. Ask your doctor whether Wegovy, the weight-management version of the same medicine, is right for you, and check whether your state covers it.
Does Medicaid cover Ozempic for prediabetes?
Prediabetes alone does not meet a type 2 diabetes coverage rule. Ask your doctor which treatment and covered-use rule fit your actual diagnosis, and when to re-test if needed.
Do I have to try metformin first?
It depends on the policy and the reason for treatment. Florida, Indiana, South Carolina, Oregon's FFS program, and Alaska's clinical-review pathway include metformin rules with medical exceptions. Georgia's current FFS Ozempic section does not list a metformin-first step. TennCare's October form also does not list one for the preferred injection; ask about any other claim requirements. Some non-preferred requests need preferred-drug trials or an exception instead.
Can I use the Ozempic $25 savings card with Medicaid?
No. Novo's commercial-insurance copay offer excludes Medicaid members. A denied Ozempic claim does not change that. The separate NovoCare Pharmacy self-pay program has different terms.
Can I buy Ozempic with cash while I'm on Medicaid?
Yes, through NovoCare Pharmacy, if it's prescribed for an FDA-approved use. The $199 pen offer covers the first two eligible 28-day fills of 0.25 or 0.5 mg for patients who have never filled Ozempic injection through NovoCare Pharmacy or NovoCare Legacy Pharmacy. The prescription must be written and received by December 31, 2026, and shipped by January 31, 2027. Standard pen prices are $349 or $499 per box, depending on strength. You can't bill Medicaid for it afterward.
Does Medicaid cover the Ozempic pill?
It can, but the pill's status and approval rules can differ from the pen. Florida, Illinois, Nevada, North Dakota, and Pennsylvania list the pill as preferred. Ask about the exact product on your prescription and your program's clinical rules.
My state cut weight-loss coverage. Is my diabetes Ozempic safe?
A weight-loss exclusion does not settle diabetes coverage. California, for example, kept Ozempic for type 2 diabetes after ending weight-loss-only coverage for members age 21 and older. Check the exact product's rules and that the claim carries your documented diagnosis.
I have Medicare and Medicaid. Who pays for Ozempic?
If you have Medicare and full Medicaid, your prescription benefit generally comes through a Medicare drug plan, with Extra Help on costs. Check that plan's Ozempic criteria; having both programs does not guarantee approval.
Can I appeal a Medicaid Ozempic denial?
Yes. Get the reason in writing, follow the deadline on your notice — generally 60 days for a Medicaid health plan appeal — and ask your doctor to fix any missing records. If waiting could seriously harm your health, ask for a fast decision.
Sources
The following sources support the findings checked October 22, 2026. Links in the unresolved-state table are lookup routes, not verified Ozempic coverage findings.
- FDA-approved labeling: Ozempic injection (revised May 2026); Ozempic tablets (revised January 2026)
- Federal law: Social Security Act §1927; 42 CFR 447.53 — Medicaid copays; 42 CFR 438.402 — managed-care appeals; 42 CFR 438.408 — appeal timing; 42 CFR 438.420 — continued benefits; 42 CFR 431.220 — state hearings
- Federal programs: Medicaid Drug Rebate Program; Medicare.gov — Medicaid and Medicare; Medicare GLP-1 Bridge; EPSDT; CMS BALANCE Model; CMS work-requirement rule summary (June 1, 2026); Medicaid.gov state contacts
- State documents: linked beside each finding, with each document's own date. Utah's weight-loss cutoff is supported by its May 2026 state bulletin, read through a publicly available copy. The Massachusetts cutoff is supported by UnitedHealthcare Community Plan's June 22 implementation notice
- Novo Nordisk: NovoCare Pharmacy terms and prices; Ozempic commercial copay offer; Patient Assistance Program; current injection list-price explanation; 2027 list-price announcement (February 24, 2026); Ozempic tablet launch announcement (May 1, 2026)
- Compounding: FDA's current shortage and compounding policies; FDA's concerns about unapproved GLP-1 drugs
- Ro: current insurance and Medicaid eligibility; free coverage checker
- The RX Index: Find My GLP-1 Path — how it works (updated October 16, 2026)
Still not sure which GLP-1 path fits you? Take The RX Index's free Find My GLP-1 Path quiz — about 2 minutes, no signup.